PEG

SHP2-D26 is a pioneering and effective degrader of SHP2, operating through its binding interactions with both VHL-1 and SHP2 proteins. The mechanism of action relies on neddylation and the proteasome pathway for inducing SHP2 degradation.

KTX-951 is a PROTAC designed to selectively degrade IRAK4, demonstrating effective performance in cellular assays. This compound exhibits notable oral bioavailability in preclinical models, indicating its potential for effective systemic delivery. Additionally, KTX-951 shows promise in anticancer applications due to its mechanism of action.

(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual-target PROTAC that facilitates the ubiquitination and degradation of Smad3 while enhancing the levels of HIF-α protein. This compound exhibits multifunctional properties, contributing to anti-fibrosis effects and offering protective benefits for renal tissues, making it a valuable tool for research in renal anemia.

dBET23 is a potent and selective PROTAC designed to degrade the BRD4 protein. Its structural composition enables effective targeting of BRD4, facilitating its degradation through the ubiquitin-proteasome system. This compound's specificity makes it a valuable tool for studying BRD4-related biological processes.

PROTAC RAR Degrader-1 consists of a binding group for IAP, a linker, and a ligand specific to retinoic acid receptors (RAR). This compound functions as a degrader of RAR, utilizing the ubiquitin-proteasome system for targeted degradation. The use of cIAP1-based degradation inducers, known as SNIPERs, enhances the specificity of this approach in protein modulation.

PROTAC BET Degrader-3 consists of ligands that link von Hippel-Lindau and bromodomain and extraterminal (BET) proteins. This structure facilitates targeted protein degradation through the ubiquitin-proteasome system, leveraging the functional properties of its components for effective cellular interactions.

ARD-1676 is an orally bioavailable PROTAC designed for degrading the androgen receptor (AR). It comprises a ligand that targets AR and a cereblon ligand, facilitating the degradation process through the ubiquitin-proteasome system. This compound demonstrates effective AR degradation both in vitro and in vivo, contributing to the inhibition of tumor growth in mouse xenograft models.

OARV-771 is a derivative of ARV-771, which is a potent PROTAC targeting bromodomain and extraterminal (BET) proteins, utilizing the von Hippel-Lindau E3 ligase for targeted degradation. This compound features selective binding affinity for various BRD proteins, demonstrating its potential utility in research focused on modulating BET protein functions.

Thalidomide-NH-CBP/p300 ligand 2 is a PROTAC designed to induce the degradation of CBP and p300 through targeted protein degradation mechanisms.